Researchers have identified a substance in female ginseng that hinders the development of cells responsible for bone tissue loss in osteoporosis. The findings appeared in the ACS Center for Science publication.
Two new compounds, falcarinphthalides A and B, were found in extracts from female ginseng, also known as the root often referred to as Chinese angelica or Angelica sinensis. Scientists managed to produce this compound in laboratory quantities suitable for biological testing.
Laboratory experiments on cells showed that falcarinphthalide A and its precursors reduced the activity of osteoclasts, the cells central to bone resorption. The compound disrupted key molecular pathways involved in osteoclast formation.
The study suggests the potential for new osteoporosis therapies based on a substance derived from female ginseng. Osteoporosis is marked by bone loss and can lead to fractures in the hip and spine.
Data from the International Osteoporosis Foundation indicate that low bone mass affects 54 million American adults over age 50. While various medications have proven effective at preventing bone loss or stimulating bone formation, all carry potential side effects, including risks to jawbone and leg health. [Citation: ACS Center for Science]
Recent summaries indicate that quitting smoking and staying physically active can lower hip fracture risk by a substantial margin, estimated at around 45 percent. [Citation: ACS Center for Science]